Cardio Onc year in review
JACC: CardioOncology, 2024, Year-in-review, most viewed papers, best of 2024
Related Articles
Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
US Surgeon General calls for cancer warning labels on alcohol
As one of his final acts under the outgoing administration of US President Joe Biden, Surgeon General Vivek Murthy has called for cancer warnings to…
Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms
Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, discuss the development and evaluation of a…
Pharma & Biotech Alliance Manager Position At EORTC
The Pharma & Biotech Alliance manager is a Medical Doctor who works under the hierarchical supervision of the Headquarters Director.
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid Leukemia
Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
AUA 2024: Disrupting the Field of Urology
Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
